ARVO | articles

During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

According to Sunil Srivastava, MD, optical coherence tomography characteristics may be predictive of the efficacy of the injections.

During ARVO’s 2021 virtual annual meeting, John Wells, MD, presented efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials.

Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator during a virtual presentation at ARVO.

During a presentation at ARVO, Jessica Liu explained that patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

Investigators review changes in ocular anterior segment blood flow and temperature after treatment of patients with meibomian gland dysfunction.